Coreline Soft plans to introduce its chest AI platform at RSNA 2025.
Called AVIEW 2.0, the system combines lung-cancer screening (LCS), coronary-artery calcium (CAC) scoring, and chronic obstructive pulmonary disease (COPD) quantification into a single, continuous analytical pipeline, according to the firm.
The company highlighted "national-scale validation" in Europe. In addition, UMass Memorial Medical Center has deployed the system for LCS, CAC, and COPD diagnosis, the company noted, adding that Temple Lung Center, 3DR Labs, and ImageCare Radiology have incorporated AVIEW into their research and diagnostic environments, each adapting AI functions to site-specific workflows and physician preferences.
At RSNA 2025, Coreline will conduct an end-to-end AI workflow demonstration in the "Radiology Reimagined" demo zone. The meeting will take place from Sunday, November 30, through Thursday, December 4.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
